Palantir will soon help the FDA evaluate drugs, including COVID-19 treatments

Palantir will soon help the FDA evaluate drugs, including COVID-19 treatments

Although it isn’t clear if the Biden administration will continue to expand federal work with Palantir, the process of distributing vaccines provides another logistical opportunity for the controversial company. Tracking which individuals have received both doses of a vaccine is work that sounds very much in Palantir’s wheelhouse.

People who get injured from COVID-19 vaccines could have a hard time getting compensated

People who get injured from COVID-19 vaccines could have a hard time getting compensated

Not only does CICP deny compensation for pain and suffering and attorney’s fees, and the right to appeals, it prohibits litigants from holding hearings and introducing evidence and expert testimony. Another CICP disadvantage, Pop said, is that the only the government’s own expert can form the basis for what constitutes a permissible claim. Therefore, he said, under the CICP program, it seems highly unlikely that any individual with a reaction that’s not “open and notorious, even though rare,” could ever get any kind of compensation.